Conn P Michael, Ulloa-Aguirre Alfredo
Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Adv Pharmacol. 2011;62:109-41. doi: 10.1016/B978-0-12-385952-5.00008-7.
Structural alterations provoked by mutations or genetic variations in the gene sequence of G protein-coupled receptors (GPCRs) may lead to abnormal function of the receptor molecule. Frequently, this leads to disease. While some mutations lead to changes in domains involved in agonist binding, receptor activation, or coupling to effectors, others may cause misfolding and lead to retention/degradation of the protein molecule by the quality control system of the cell. Several strategies, including genetic, chemical, and pharmacological approaches, have been shown to rescue function of trafficking-defective misfolded GPCRs. Among these, pharmacological strategies offer the most promising therapeutic tool to promote proper trafficking of misfolded proteins to the plasma membrane (PM). Pharmacological chaperones or "pharmacoperones" are small compounds that permeate the PM, enter cells, and bind selectively to misfolded proteins and correct folding allowing routing of the target protein to the PM, where the receptor may bind and respond to agonist stimulation. In this review, we describe new therapeutic opportunities based on mislocalization of otherwise functional human gonadotropin-releasing hormone receptors. This particular receptor is highly sensitive to single changes in chemical charge, and its intracellular traffic is delicately balanced between expression at the PM or retention/degradation in the endoplasmic reticulum; it is, therefore, a particularly instructive model to understand both the protein routing and the molecular mechanisms, whereby pharmacoperones rescue misfolded intermediates or conformationally defective receptors.
G蛋白偶联受体(GPCRs)基因序列中的突变或基因变异引发的结构改变可能导致受体分子功能异常。这常常会引发疾病。虽然一些突变会导致参与激动剂结合、受体激活或与效应器偶联的结构域发生变化,但其他突变可能会导致错误折叠,并通过细胞的质量控制系统导致蛋白质分子滞留/降解。包括基因、化学和药理学方法在内的几种策略已被证明可挽救有转运缺陷的错误折叠GPCRs的功能。其中,药理学策略为促进错误折叠蛋白正确转运到质膜(PM)提供了最有前景的治疗工具。药理学伴侣或“药效伴侣”是小分子化合物,它们可穿透质膜,进入细胞,选择性地与错误折叠的蛋白结合并纠正折叠,使靶蛋白能够转运到质膜,在那里受体可以结合并对激动剂刺激作出反应。在本综述中,我们描述了基于原本功能正常的人促性腺激素释放激素受体定位错误而产生的新治疗机会。这种特定的受体对化学电荷的单一变化高度敏感,其细胞内转运在质膜表达或在内质网中滞留/降解之间微妙地平衡;因此,它是理解蛋白质转运和分子机制的一个特别有启发性的模型,通过该模型可以了解药效伴侣如何挽救错误折叠的中间体或构象缺陷的受体。